Profile data is unavailable for this security.
About the company
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
- Revenue in USD (TTM)234.00k
- Net income in USD-160.30m
- Incorporated2015
- Employees141.00
- LocationKeros Therapeutics Inc1050 Waltham Street, Suite 302LEXINGTON 02421United StatesUSA
- Phone+1 (617) 314-6297
- Websitehttps://www.kerostx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neumora Therapeutics Inc | 0.00 | -254.02m | 1.52bn | 120.00 | -- | 3.57 | -- | -- | -1.55 | -1.55 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -60.32 | -- | -63.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Edgewise Therapeutics Inc | 0.00 | -105.85m | 1.59bn | 92.00 | -- | 2.97 | -- | -- | -1.53 | -1.53 | 0.00 | 5.73 | 0.00 | -- | -- | 0.00 | -23.52 | -- | -24.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Kura Oncology Inc | 0.00 | -168.09m | 1.60bn | 142.00 | -- | 3.16 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
| Akero Therapeutics Inc | 0.00 | -179.27m | 1.60bn | 58.00 | -- | 1.90 | -- | -- | -3.20 | -3.20 | 0.00 | 12.24 | 0.00 | -- | -- | 0.00 | -28.43 | -37.73 | -29.53 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0395 | -- | -- | -- | -35.46 | -- | -- | -- |
| Keros Therapeutics Inc | 234.00k | -160.30m | 1.68bn | 141.00 | -- | 3.69 | -- | 7,161.26 | -5.14 | -5.14 | 0.0075 | 12.59 | 0.0005 | -- | -- | 1,720.59 | -36.84 | -35.95 | -38.35 | -38.07 | -- | -- | -68,505.13 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Syndax Pharmaceuticals Inc | 0.00 | -240.63m | 1.70bn | 112.00 | -- | 3.46 | -- | -- | -3.22 | -3.22 | 0.00 | 5.79 | 0.00 | -- | -- | 0.00 | -47.99 | -27.90 | -51.84 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
| Harmony Biosciences Holdings Inc | 617.51m | 137.70m | 1.71bn | 246.00 | 13.01 | 3.32 | 10.55 | 2.77 | 2.32 | 2.32 | 10.39 | 9.08 | 0.7906 | 25.72 | 9.34 | 2,510,207.00 | 17.63 | 7.46 | 20.83 | 9.08 | 79.28 | 80.58 | 22.30 | 10.46 | 3.07 | 31.38 | 0.2694 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Arvinas Inc | 71.30m | -354.80m | 1.73bn | 445.00 | -- | 2.83 | -- | 24.21 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Immunocore Holdings PLC - ADR | 265.83m | -59.44m | 1.80bn | 497.00 | -- | 4.97 | -- | 6.76 | -1.20 | -1.20 | 5.27 | 7.23 | 0.3486 | 0.406 | 5.60 | 534,860.40 | -7.80 | -27.55 | -9.40 | -36.82 | 99.60 | -- | -22.36 | -97.12 | 5.94 | -- | 0.5489 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Maravai Lifesciences Holdings Inc | 274.10m | -131.04m | 1.82bn | 570.00 | -- | 4.44 | -- | 6.65 | -0.9917 | -0.9917 | 2.08 | 1.63 | 0.1458 | 2.93 | 5.90 | 421,690.80 | -8.49 | 12.67 | -11.29 | 15.46 | 44.03 | 74.79 | -58.27 | 37.32 | 10.47 | -2.02 | 0.4169 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 4.36m | 12.09% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.87m | 5.17% |
| Alkeon Capital Management LLCas of 31 Mar 2024 | 1.60m | 4.43% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.56m | 4.33% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.47m | 4.09% |
| Darwin Global Management Ltd.as of 31 Mar 2024 | 1.44m | 3.98% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 1.20m | 3.33% |
| Point72 Asset Management LPas of 31 Mar 2024 | 971.88k | 2.69% |
| Silverbay Capital Management LLCas of 31 Mar 2024 | 784.10k | 2.17% |
| Woodline Partners LPas of 31 Mar 2024 | 761.70k | 2.11% |
